SOS GEFs in health and disease

被引:66
作者
Baltanas, Fernando C. [1 ]
Zarich, Natasha [2 ]
Rojas-Cabaneros, Jose M. [2 ]
Santos, Eugenio [1 ]
机构
[1] Univ Salamanca, Ctr Invest Canc IBMCC CSIC USAL & CIBERONC, Salamanca 37007, Spain
[2] Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron UFIEC & CIBE, Madrid 28220, Spain
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2020年 / 1874卷 / 02期
关键词
SOS1; SOS2; RASGEF; RAS; Cancer; Rasopathies; GUANINE-NUCLEOTIDE EXCHANGE; RAS ACTIVATOR SON; HEREDITARY GINGIVAL FIBROMATOSIS; SIGNAL-REGULATED KINASE; TERMINAL SH3 DOMAIN; NOONAN-SYNDROME; EGF RECEPTOR; ONCOGENIC KRAS; PHOSPHORYLATION SITES; PATHWAY ACTIVATION;
D O I
10.1016/j.bbcan.2020.188445
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SOS1 and SOS2 are the most universal and widely expressed family of guanine exchange factors (GEFs) capable or activating RAS or RAC1 proteins in metazoan cells. SOS proteins contain a sequence of modular domains that are responsible for different intramolecular and intermolecular interactions modulating mechanisms of selfinhibition, allosteric activation and intracellular homeostasis. Despite their homology, analyses of SOS1/2-KO mice demonstrate functional prevalence of SOS1 over SOS2 in cellular processes including proliferation, migration, inflammation or maintenance of intracellular redox homeostasis, although some functional redundancy cannot be excluded, particularly at the organismal level. Specific SOS1 gain-of-function mutations have been identified in inherited RASopathies and various sporadic human cancers. SOS1 depletion reduces tumorigenesis mediated by RAS or RAC1 in mouse models and is associated with increased intracellular oxidative stress and mitochondrial dysfunction. Since WT RAS is essential for development of RAS-mutant tumors, the SOS GEFs may be considered as relevant biomarkers or therapy targets in RAS-dependent cancers. Inhibitors blocking SOS expression, intrinsic GEF activity, or productive SOS protein-protein interactions with cellular regulators and/or RAS/RAC targets have been recently developed and shown preclinical and clinical effectiveness blocking aberrant RAS signaling in RAS-driven and RTK-driven tumors.
引用
收藏
页数:24
相关论文
共 299 条
[1]   Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS [J].
Abbott, Jason R. ;
Patel, Pratiq A. ;
Howes, Jennifer E. ;
Akan, Denis T. ;
Kennedy, J. Phillip ;
Burns, Michael C. ;
Browning, Carrie F. ;
Sun, Qi ;
Rossanese, Olivia W. ;
Phan, Jason ;
Waterson, Alex G. ;
Fesik, Stephen W. .
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (09) :941-946
[2]   Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling [J].
Abbott, Jason R. ;
Hodges, Timothy R. ;
Daniels, R. Nathan ;
Patel, Pratiq A. ;
Kennedy, J. Phillip ;
Howes, Jennifer E. ;
Akan, Denis T. ;
Burns, Michael C. ;
Sai, Jiqing ;
Sobolik, Tammy ;
Beesetty, Yugandhar ;
Lee, Taekyu ;
Rossanese, Olivia W. ;
Phan, Jason ;
Waterson, Alex G. ;
Fesik, Stephen W. .
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (14) :6002-6017
[3]   Highly reproducible improved label-free quantitative analysis of cellular phosphoproteome by optimization of LC-MS/MS gradient and analytical column construction [J].
Ahsan, Nagib ;
Belmont, Judson ;
Chen, Zhuo ;
Clifton, James G. ;
Salomon, Arthur R. .
JOURNAL OF PROTEOMICS, 2017, 165 :69-74
[4]   Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses [J].
Akan, Denis T. ;
Howes, Jennifer E. ;
Sai, Jiqing ;
Arnold, Allison L. ;
Beesetty, Yugandhar ;
Phan, Jason ;
Olejniczak, Edward T. ;
Waterson, Alex G. ;
Fesik, Stephen W. .
ACS CHEMICAL BIOLOGY, 2019, 14 (03) :325-331
[5]   Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143 [J].
Akao, Yukihiro ;
Kumazaki, Minami ;
Shinohara, Haruka ;
Sugito, Nobuhiko ;
Kuranaga, Yuki ;
Tsujino, Takuya ;
Yoshikawa, Yuki ;
Kitade, Yukio .
CANCER SCIENCE, 2018, 109 (05) :1455-1467
[6]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[7]   MiR-148a impairs Ras/ERK signaling in B lymphocytes by targeting SOS proteins [J].
Alles, Julia ;
Ludwig, Nicole ;
Rheinheimer, Stefanie ;
Leidinger, Petra ;
Graesser, Friedrich A. ;
Keller, Andreas ;
Meese, Eckart .
ONCOTARGET, 2017, 8 (34) :56417-56427
[8]   Local phosphatidylinositol 3,4,5-trisphosphate accumulation recruits Vav2 and Vav3 to activate Rac1/Cdc42 and initiate neurite outgrowth in nerve growth factor-stimulated PC12 cells [J].
Aoki, K ;
Nakamura, T ;
Fujikawa, K ;
Matsuda, M .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (05) :2207-2217
[9]   Sos2 is dispensable for NMDA-induced Erk activation and LTP induction [J].
Arai, Junko A. ;
Li, Shaomin ;
Feig, Larry A. .
NEUROSCIENCE LETTERS, 2009, 455 (01) :22-25
[10]   p66shc inhibits pro-survival epidermal growth factor receptor/ERK signaling during severe oxidative stress in mouse renal proximal tubule cells [J].
Arany, Istvan ;
Faisal, Amir ;
Nagamine, Yoshikuni ;
Safirstein, Robert L. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (10) :6110-6117